Global Inhaler Market 2025-2035

Description

List of Tables

Inhaler Market Size, Share & Trends Analysis Report by Type (Metered-dose, Dry powder, and Soft mist inhalers), by Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, and Others), and by Distribution Channel (Online and Offline), Forecast Period (2025-2035)

Industry Overview

Inhaler market was valued at $36.2 billion in 2024 and is projected to reach $71.4 billion by 2035, growing at a CAGR of 5.9% during the forecast period (2025-2035). The global inhaler market is gaining strong momentum owing to the advancements in inhaler technology, rising prevalence of respiratory diseases, growing air pollution and allergens, increasing awareness and diagnosis, and expanding healthcare infrastructure in emerging markets. Asthma is a major contributor to the growth of the inhaler market, considering it is a chronic respiratory condition that affects millions of individuals globally and necessitates the use of inhalers regularly for effective treatment. Inhalers provide medication directly to the lungs, offering fast relief from symptoms and aiding in the control of asthma attacks. Asthma is one of the most prevalent chronic non-communicable diseases, affecting over 334 million people and accounting for over 450,000 casualties annually across the globe, the majority of which are preventable.

Market Dynamics

Digital Health Integration and Smart Inhaler Adoption

The increasing integration of inhalers with digital health technologies, such as Bluetooth connectivity, mobile health (mHealth) applications, and AI-powered adherence tracking systems, is a rapidly expanding trend in the respiratory inhalers market. For chronic respiratory conditions, the combination is enhancing patient involvement, facilitating remote monitoring, and boosting treatment results. For instance, in August 2023, Teva UK launched GoResp Digihaler (an integrated digital inhaler system), which allows appropriate adult patients with asthma and COPD to help self-manage their condition and share their data with healthcare professionals. Budesonide and formoterol fumarate dihydrate are combined in the GoResp Digihaler, an integrated device with sensors to identify and document objective data on the patient's use and proficiency with their inhaler, including the classification of inspiratory flow.

The High Price of Respiratory Inhalers Can Hamper the Inhalers Market Growth

The prevalence of respiratory disorders remains extremely high globally, and the cost of treatment has been steadily increasing. The high cost of inhalers makes it difficult for many people to afford prescribed treatments regularly. This is a major concern, particularly in nations where a large portion of the population lacks health insurance or the financial resources to pay for pricey prescription drugs out of pocket.

The price of asthma medication has increased in nations such as the US over the past decade and a half. The price increase, which can range from slightly more than $10 to nearly $100 for an inhaler, has made it difficult for patients in need of asthma-related treatments to obtain them. Others simply cannot afford them. Since 2009, CFC inhalers have been phased out and replaced by hydrofluoroalkane, or HFA, inhalers, which are more environmentally friendly but significantly more expensive. Patients with good insurance may pay little or nothing. However, uninsured patients confront high market prices, and as of 2023, there were more than 25 million uninsured Americans.

Market Segmentation

Based on the type, the market is segmented into metered-dose, dry powder, and soft mist inhalers.
Based on the disease indication, the market is segmented into asthma, COPD, cystic fibrosis, and others.
Based on the distribution channel, the market is segmented into online and offline.

Asthma Accounts for the Largest Share of the Global Inhaler Market

Asthma accounts for the largest share of the global inhaler market, driven by the high global prevalence of the condition and increasing patient awareness about early treatment to prevent exacerbations.

Asthma Statistics: Prevalence, Economic Impact, and Mortality Trends

Asthma is the most prevalent non-communicable disease (NCD) affecting children - around 1 in 10 children have the disease. It remains common through adulthood, affecting around 1 in 15 adults.
In 2023, adult asthma prevalence varied by state in the US, ranging from 7.1% in Mississippi to 14.1% in Puerto Rico.
In the UK, 7.2 million individuals have asthma. This is about 8 in every 100 individuals.
In the US, Asthma prevalence is higher in adults (8.0%) than in children (6.5%), and higher in females (9.7 %) than in males (6.2%).
The estimated economic cost of asthma is $50 billion annually in the US.
In the US, every year, more than 3,500 fatalities are caused by asthma each year, nearly a third of whom are age 65 or older. Recent statistics show that half of individuals with asthma have at least one asthma attack each year, with adults (39.6%) more likely to have an attack than children (38.7%).

Metered-Dose Inhalers (MDIs): A Key Segment in Market Growth

The metered dose inhaler is the leading segment in the market, driven by its widespread availability, affordability, and proven effectiveness in delivering quick relief for acute respiratory symptoms. MDIs are particularly common in low and middle-income nations since they are typically less expensive to manufacture and purchase. MDIs are widely used as they have been on the market for decades and are well-known to patients and healthcare providers.

Regional Outlook

The global inhaler market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Leading the Global Inhaler Market Growth

North America dominates the respiratory inhalers market owing to the easy-to-use inhalers with digital dose tracking and smart connectivity, a growing geriatric population susceptible to chronic respiratory conditions, and the presence of major pharmaceutical companies such as AstraZeneca, GSK, Teva, Chiesi, and Sunovion, which provide the region with easy access to the most innovative portfolio of inhalers. Respiratory and immunology medications, such as inhalers, make up a large amount of these companies' annual revenue. For instance, in 2023, AstraZeneca's Breztri Aerosphere generated approximately. $383 million in US sales, a major inhaler revenue driver as a modern triple-therapy device.

Furthermore, the US market has recently seen the entry of numerous technologically upgraded inhalers that incorporate digital connectivity, environmental sustainability, and improved patient adherence. Currently, market players have been incorporating Bluetooth-enabled sensors attached to the inhaler, which track medication usage, including the inhalation patterns such as flow rate and duration, with date and time of actuations. For instance, the FDA has cleared the Hailie Smartinhaler for use with AstraZeneca's Airsupra (albuterol and budesonide) and Breztri Aerosphere (budesonide, glycopyrrolate, and formoterol fumarate) inhalation devices. The Bluetooth-enabled Hailie sensor is attached to the inhaler and then synced with the Hailie app. The system is intended to aid in treatment adherence by tracking medication consumption and alerting patients if a dose is missed.

Asia-Pacific Leads Inhaler Market Growth amid Rising Respiratory Disease Burden

The Asia-Pacific region maintains a strong market position in the inhaler industry owing to the growing burden of asthma, COPD, and other respiratory conditions, major investments by pharmaceutical companies, awareness campaigns & enhanced healthcare infrastructure, and rapidly aging populations, especially in markets like Japan. In 2023, India accounts for nearly 46% of global asthma-related fatalities, with an estimated 200,000 individuals succumbing to the disease each year. In India, asthma cases have been increasing rapidly, particularly in tier-I and II cities such as Hyderabad, Warangal, and Karimnagar. Over 1.8 million individuals in Telangana are living with asthma, with children and women being the most vulnerable groups. Pharmaceutical companies in the region are responding to the increased demand by increasing the availability and variety of inhalers, making them more accessible to patients. This trend is projected to continue as the prevalence of respiratory disorders increases, driving up demand for inhaler devices in Asia-Pacific nations.

Market Players Outlook

The major companies operating in the global inhaler market include GlaxoSmithKline PLC, Cipla Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In May 2024, DevPro Biopharma and Bespak announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurized metered dose inhaler (pMDI), which shows comparable performance to Ventolin HFA, with a significant reduction in greenhouse gas emissions.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global inhaler market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2025504

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Inhaler Market Sales Analysis - Type | Disease Indication | Distribution Channel ($ Million)
Inhaler Market Sales Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Inhaler Market Trends
- 2.2.2. Market Recommendations

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For the Global Inhaler Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For the Global Inhaler Market: Impact Analysis
3.3. Market Opportunities
- 3.3.1. Opportunities For the Global Inhaler Market: Impact Analysis

4. Competitive Landscape

4.1. Competitive Dashboard - Inhaler Market Revenue and Share by Manufacturers
Inhaler Product Type Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. AstraZeneca PLC
  - 4.2.1.1. Overview
  - 4.2.1.2. Battery Type Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Boehringer Ingelheim Pharmaceuticals, Inc
  - 4.2.2.1. Overview
  - 4.2.2.2. Battery Type Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Cipla Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Battery Type Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. GlaxoSmithKline PLC
  - 4.2.4.1. Overview
  - 4.2.4.2. Battery Type Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Teva Pharmaceutical Industries Ltd.
  - 4.2.5.1. Overview
  - 4.2.5.2. Battery Type Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Battery Type Launch
- 4.3.3. Partnership And Collaboration

5. Global Inhaler Market Sales Analysis By Type ($ Million)

5.1. Metered-dose
5.2. Dry powder
5.3. Soft mist inhalers

6. Global Inhaler Market Sales Analysis By Disease Indication ($ Million)

6.1. Asthma
6.2. Chronic Obstructive Pulmonary Disease (COPD)
6.3. Cystic Fibrosis
6.4. Others (Pulmonary Arterial Hypertension (PAH), Non-Respiratory Conditions)

7. Global Inhaler Market Sales Analysis By Distribution Channel ($ Million)

7.1. Offline
7.2. Online

8. Regional Analysis

8.1. North American Inhaler Market Sales Analysis - Type | Disease Indication| Distribution Channel | Country ($ Million)
Macroeconomic Factors for North America
- 8.1.1. United States
- 8.1.2. Canada
8.2. European Inhaler Market Sales Analysis - Type | Disease Indication| Distribution Channel| Country ($ Million)
Macroeconomic Factors for Europe
- 8.2.1. UK
- 8.2.2. Germany
- 8.2.3. Italy
- 8.2.4. Spain
- 8.2.5. France
- 8.2.6. Russia
- 8.2.7. Rest of Europe
8.3. Asia-Pacific Inhaler Market Sales Analysis - Type | Disease Indication| Distribution Channel | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. South Korea
- 8.3.4. India
- 8.3.5. Australia & New Zealand
- 8.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 8.3.7. Rest of Asia-Pacific
8.4. Rest of the World Inhaler Market Sales Analysis - Type | Disease Indication| Distribution Channel | Country ($ Million)
Macroeconomic Factors for the Rest of the World
- 8.4.1. Latin America
- 8.4.2. Middle East and Africa

9. Company Profiles

9.1. Actiza Pharmaceutical Pvt. Ltd
- 9.1.1. Quick Facts
- 9.1.2. Company Overview
- 9.1.3. Product Portfolio
- 9.1.4. Business Strategies
9.2. AptarGroup Inc.
- 9.2.1. Quick Facts
- 9.2.2. Company Overview
- 9.2.3. Product Portfolio
- 9.2.4. Business Strategies
9.3. AstraZeneca PLC
- 9.3.1. Quick Facts
- 9.3.2. Company Overview
- 9.3.3. Product Portfolio
- 9.3.4. Business Strategies
9.4. Bespak Ltd.
- 9.4.1. Quick Facts
- 9.4.2. Company Overview
- 9.4.3. Product Portfolio
- 9.4.4. Business Strategies
9.5. Beximco Pharmaceuticals Ltd.
- 9.5.1. Quick Facts
- 9.5.2. Company Overview
- 9.5.3. Product Portfolio
- 9.5.4. Business Strategies
9.6. BreatheSuite Inc.
- 9.6.1. Quick Facts
- 9.6.2. Company Overview
- 9.6.3. Product Portfolio
- 9.6.4. Business Strategies
9.7. Boehringer Ingelheim Pharmaceuticals, Inc.
- 9.7.1. Quick Facts
- 9.7.2. Company Overview
- 9.7.3. Product Portfolio
- 9.7.4. Business Strategies
9.8. Cipla Ltd.
- 9.8.1. Quick Facts
- 9.8.2. Company Overview
- 9.8.3. Product Portfolio
- 9.8.4. Business Strategies
9.9. CHIESI Farmaceutici S.p.A.
- 9.9.1. Quick Facts
- 9.9.2. Company Overview
- 9.9.3. Product Portfolio
- 9.9.4. Business Strategies
9.10. FindAir Sp. z o.o
- 9.10.1. Quick Facts
- 9.10.2. Company Overview
- 9.10.3. Product Portfolio
- 9.10.4. Business Strategies
9.11. GlaxoSmithKline PLC
- 9.11.1. Quick Facts
- 9.11.2. Company Overview
- 9.11.3. Product Portfolio
- 9.11.4. Business Strategies
9.12. Hovione
- 9.12.1. Quick Facts
- 9.12.2. Company Overview
- 9.12.3. Product Portfolio
- 9.12.4. Business Strategies
9.13. Iconovo AB
- 9.13.1. Quick Facts
- 9.13.2. Company Overview
- 9.13.3. Product Portfolio
- 9.13.4. Business Strategies
9.14. Kindeva Drug Delivery L.P
- 9.14.1. Quick Facts
- 9.14.2. Company Overview
- 9.14.3. Product Portfolio
- 9.14.4. Business Strategies
9.15. Lupin Pharmaceuticals, Inc.
- 9.15.1. Quick Facts
- 9.15.2. Company Overview
- 9.15.3. Product Portfolio
- 9.15.4. Business Strategies
9.16. Merxin Ltd
- 9.16.1. Quick Facts
- 9.16.2. Company Overview
- 9.16.3. Product Portfolio
- 9.16.4. Business Strategies
9.17. Medisol Lifescience Pvt. Ltd
- 9.17.1. Quick Facts
- 9.17.2. Company Overview
- 9.17.3. Product Portfolio
- 9.17.4. Business Strategies
9.18. Mylan Pharmaceuticals Inc
- 9.18.1. Quick Facts
- 9.18.2. Company Overview
- 9.18.3. Product Portfolio
- 9.18.4. Business Strategies
9.19. Novartis AG
- 9.19.1. Quick Facts
- 9.19.2. Company Overview
- 9.19.3. Product Portfolio
- 9.19.4. Business Strategies
9.20. Organon & Co
- 9.20.1. Quick Facts
- 9.20.2. Company Overview
- 9.20.3. Product Portfolio
- 9.20.4. Business Strategies
9.21. Sava Healthcare Ltd
- 9.21.1. Quick Facts
- 9.21.2. Company Overview
- 9.21.3. Product Portfolio
- 9.21.4. Business Strategies
9.22. Teva Pharmaceutical Industries Ltd.
- 9.22.1. Quick Facts
- 9.22.2. Company Overview
- 9.22.3. Product Portfolio
- 9.22.4. Business Strategies
9.23. Zydus Healthcare Ltd.
- 9.23.1. Quick Facts
- 9.23.2. Company Overview
- 9.23.3. Product Portfolio
- 9.23.4. Business Strategies